Exabis Library
Welcome to the e-CCO Library!
P564: Low-dose azathioprine improves long-term efficacy of infliximab maintenance treatment in Japanese patients with Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P564: Significant reduction of admission time at the IBD infusion unit by an e-health pre-admission assessment and order system for intravenous therapy
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P564: Validation of the IBD-Disk instrument in a Portuguese cohort
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P564: vedolizumab versus infliximab and adalimumab in the real-world persistence in Ulcerative Colitis and Crohn's disease – a meta-analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P565 Efficacy and safety of long-term treatment with ustekinumab in moderate–severe ulcerative colitis patients with delayed response to ustekinumab induction: Results from UNIFI 2-year long-term extension
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P565: Assessments of clinical efficacy and mucosal healing in ulcerative colitis patients undergoing granulomonocytapheresis at different treatment frequencies
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P565: Comparison of the efficacy of adalimumab and ustekinumab for prevention of intestinal fibrosis in bio-naive Crohn's Disease patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P565: COVID-19 vaccination satisfaction and hesitancy in patients with inflammatory bowel disease: “inside referral center” survey
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P565: Illness perception as a clinical tool to detect mood disturbances (anxiety or depression) in inflammatory bowel disease patients.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P565: Infliximab therapy intensification upon loss of response: what should be the cut-off for trough levels?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P565: Real-world use of azathioprine metabolites changes clinical management of inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P566 Assessing the efficacy of biologics in ulcerative colitis: A real-life, observational retrospective multicenter study using the propensity score analysis: The ‘A.U.R.O.R.A.’ comparison study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P566: Colitis due to immunotherapy with anti-PD-1: a case series
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P566: Effect of polyethylene glycol (PEG) bowel preparation on faecal calprotectin levels in patients with ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P566: Frequency and type of drug-related side effects necessitating drug cessation in the Swiss inflammatory bowel disease cohort
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P566: Humoral immune response to mRNA COVID-19 vaccine in Puerto Ricans with IBD does not differ between class of biologics
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P566: Impact of induction therapy and clinical remission on resting energy expenditure in children with Crohn’s Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P566: The cost for IBD care during the first 5 years after diagnosis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P567 Impact of oral ferric maltol and IV iron on health-related quality of life in patients with iron deficiency anaemia and inflammatory bowel disease, and relationship with haemoglobin and serum iron
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
Wednesday, 3 March 2021, 4:11 PM by Dauren Ramankulov
P567: Could an escalation of therapy or intervention (ETI) calculator be used to triage appointments for patients with ulcerative colitis?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM